

Lp(a), Artificial Intelligence, Hypertrophic Cardiomyopathy...

Elevated Lp(a) is an important cause of residual cardiovascular risk despite optimal LDL-C lowering and is associated with progressive ASCVD even when guideline recommended lipid targets are achieved. Yurtseven and Tokgözoğlu from Türkiye reviewed this topic and the emerging therapies.

Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide, emphasizing the ongoing need for effective and scalable primary and secondary prevention strategies. In this evolving landscape artificial intelligence (AI) has emerged as a transformative force in preventive cardiology, with the potential to reshape risk assessment, early disease detection and personalized preventive care. Keser et al from Türkiye focused on this important tool.

Balaban et al from Türkiye investigated the prognostic utility of the Index of Cardiac Electrophysiological Balance and its corrected variant in predicting ventricular arrhythmias in Hypertrophic Cardiomyopathy. Could their integration into existing risk stratification models enhance predictive accuracy, particularly for grey zone patients?

Does admission spot Urinary Na provide clinically relevant information in patients presenting with NSTEMI? Kozluca et al from Türkiye tried to answer this question.

Liang et al from China explored the effects of forest therapy on negative emotional states, oxidative stress levels, and the risk of cardiovascular disease among elderly patients with hypertension. See the results.

Hypertrophic cardiomyopathy (HCM) is a complex myocardial disorder with heterogeneous clinical presentations and structural manifestations. Babur Güler et al from Türkiye aimed to assess the distribution, clinical characteristics, and diagnostic approaches in a regional cohort of patients with HCM. Their findings emphasize the importance of cardiac imaging, genetic testing, and clinical risk stratification in understanding the heterogeneity of HCM and guiding individualized patient management in a regional area in Türkiye.

And a new case report, letters, e-page original...

I hope this new issue of our journal will be interest of our readers.

EDITORIAL

Çetin Erol

Editor-in-Chief, Ankara, Türkiye

DOI: 10.14744/AnatolJCardiol.2026.5



Copyright@Author(s) - Available online at anatoljcardiol.com.
Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.